Genentech, a subsidiary of Roche Holding AG (RHHBY), Friday announced a new 5-year data confirming benefit of Evrysdi for the children with Type 1 spinal muscular atrophy or SMA as they were able to sit, stand and walk.
SMA is a progressive neuromuscular disease that affects the functioning of nerve cells, affecting the patient's ability to walk, eat or breathe.
By the end of the Firefish study, 91 percent of children treated with Evrysdi were alive, 81 percent were alive without permanent ventilation and the majority were able to sit without support for at least 30 seconds, the company stated.
Also, 96 percent of patients were able to swallow, and 80 percent were able to feed without the help of a feeding tube by the end of 5 years.
Currently, Genentech's stock is trading at $33.92, up 1.31 percent on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Health News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.